Orgenesis signs joint venture with Cure Therapeutics to advance point-of-care development and commercialization of cell and gene therapies

Parties to collaborate on development, commercialization, and supply of the Orgenesis therapies pipeline in South Korea and Japan, and development and commercialization of the Cure Therapeutics pipeline on a global basis

Germantown, MD, US, December 9, 2020 – Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), and Cure Therapeutics, Inc. (“Cure Therapeutics”), a developer of immuno-oncology and cell and gene therapies to target cancer and infectious diseases, today announces the signing of a joint venture agreement (“Agreement”). 

The joint venture is intended to advance the development, regulatory and governmental approval, and commercialization of point of care production for both organizations’ cell and gene therapies and immunotherapies. Under the Agreement, the parties will collaborate in developing and commercializing Cure Therapeutics’ pipeline on a global basis, as well as developing, commercializing and supplying Orgenesis’ therapeutic pipeline in South Korea and Japan. In connection with the Agreement, each of Cure Therapeutics and Orgenesis will contribute at least USD 10 million to the joint venture to cover operating costs, USD 5 million of which may be provided in the form of in-kind contribution.

“This collaboration between Orgenesis and Cure Therapeutics further expands our cell and gene therapy pipeline and provides a clear illustration of the international scope of our POCare Platform,” said Vered Caplan, CEO of Orgenesis. “We selected Cure Therapeutics as our partner in South Korea and Japan given their expertise in the region, and robust immunotherapy pipeline. Additionally, this Agreement supports Orgenesis’ continued efforts to complement the Orgenesis pipeline and distribution efforts in the United States, Europe and globally.”

“The joint venture and partnership with Orgenesis will provide a significant international route to market for our immunotherapies targeting cancers and infectious diseases. Cure Therapeutics will leverage the Orgenesis POCare Network of leading international healthcare institutions to accelerate the international development and market approvals for our portfolio,” said David Kim, CEO of Cure Therapeutics. “In parallel, we will leverage our established network to help develop and rapidly advance the Orgenesis cell and gene therapy portfolio in South Korea and Japan.”

The first focus of the partnership will be aligning the efforts of both companies to advance  proprietary Orgenesis CAR-T, TILS and DUVAC therapies into clinical trials in South Korea and Japan. Process development and validation will be completed by leveraging the POCare Technologies from the Orgenesis platform to achieve automated manufacturing at the point of care. 

About Orgenesis

Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format. The Orgenesis Point of Care Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies. Learn more about the work Orgenesis is doing at www.orgenesis.com.

About Cure Therapeutics

Cure Therapeutics is a Korea-based cell and gene and immune-oncology therapy developer focused on meeting unmet medical needs by leveraging data and evidence driven drug development. The therapy portfolio features owned and in-licensed novel platform technology-based therapies to potentially cure hard to treat hematological and solid cancers, life-threatening genetic disorders, and chronic liver diseases threatening quality of life. Deep scientific, technological, technical, and regulatory knowledge are melted into a decentralized structure to deliver cutting edge new therapies to address urgent medical need diseases.